European Market Research

 
News Articles for European Market Research top ^
The Company concluded a positive scientific advice meeting with the UK MHRA regarding RHB-102 and plans to submit, during the second half of the year, a European marketing application for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients RHB-102 is a proprietary, once-daily, oral pill formulation of the anti-emetic oncology support drug ondansetron The Company commenced a comparative bioavailability study with RHB-102 to support its planned European marketing application, with study results expected by July 2014 In addition to the currently pursued indications, the MHRA provided guidance regarding a new undisclosed indication which may significantly expand RHB-102's potential market; A Phase III study for this indication is planned in the U.S. for later this year TEL-AVIV, Israel, April 7, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
Sign-up for RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application investment picks
RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers In light of the positive results, and subject to regulatory requirements, the Company plans to submit, during the third quarter of this year, a European marketing application for RHB-102 for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients RHB-102 is a proprietary, once-daily, extended release oral pill formulation of the anti-emetic oncology support drug ondansetron RedHill is also pursuing a new undisclosed indication for RHB-102, which may significantly expand its potential market, with a Phase III study planned to commence in the U.S. later this year TEL-AVIV, Israel, April 30, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
Sign-up for RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014 investment picks
2014/4/22
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- Drug makers took center stage in European trading Tuesday, with AstraZeneca PLC shares posting their best advance in nearly three years on news of a potential takeover bid, and as GlaxoSmithKline PLC climbed on the multibillion-dollar sales of a business unit.
Sign-up for UPDATE: Drug stocks drive European markets higher investment picks
2014/4/22
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- Drug makers took center stage in European trading Tuesday, with shares of AstraZeneca PLC climbing on news of a potential takeover bid, and GlaxoSmithKline PLC rising as it sells one of its units in a multibillion-dollar deal.
Sign-up for Drug stocks drive European markets higher investment picks

 
Article Quotes for European Market Research top ^
2014/06/30
European markets were slightly higher Monday.
Sign-up for European Markets Slightly Higher investment picks
2014/06/25
European markets were lower Wednesday in line with declines elsewhere in global markets on mounting concern over violence in Iraq.
Sign-up for European Markets Decline investment picks
2014/07/08
European stocks were all lower Tuesday tracking losses elsewhere in global markets and also weighed by some downbeat data out of the region.
Sign-up for European Markets Decline as Data Disappoints investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

European Market Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: European Index Funds  |  Next: European Media Enterprises